A multinational comparison of drug treatment in patients with cerebrovascular disease

A. Spagnoli; G. Tognoni; I. Darmansjah; J. R. Laporte; B. Vrhovac; D. F. Treacher; C. P. Warlow

doi:10.1159/000115754

A multinational comparison of drug treatment in patients with cerebrovascular disease

A. Spagnoli, G. Tognoni, I. Darmansjah, J. R. Laporte, B. Vrhovac, D. F. Treacher, C. P. Warlow

Research output: Contribution to journal › Article › Research › peer-review

3 Citations (Scopus)

Abstract

We have compared the frequency with which various drugs were used in patients with cerebrovascular disease in five countries (UK. Italy, Indonesia, Spain and Yugoslavia). There were very large variations in the use of anti-oedema agents, ‘cerebral vasodilators’, and vitamins, which were not explained by differences in the populations studied. This variation has probably less to do with any scientific validation for the various treatments, which in most cases does not exist, than with medical ‘fashion’ and commercial pressures. Large variations in prescribing habits for what is thought to be the same disease are undesirable, and reflect a dearth of facts and adequate clinical trials. © 1985 S. Karger AG, Basel.

Original language	English
Pages (from-to)	4-12
Journal	European Neurology
Volume	24
Issue number	1
DOIs	https://doi.org/10.1159/000115754
Publication status	Published - 1 Jan 1985

Keywords

Cerebrovascular disease
Drug treatment
Drug utilization

Access to Document

10.1159/000115754

Cite this

@article{f072327cc3d64353974611f4d086a099,

title = "A multinational comparison of drug treatment in patients with cerebrovascular disease",

abstract = "We have compared the frequency with which various drugs were used in patients with cerebrovascular disease in five countries (UK. Italy, Indonesia, Spain and Yugoslavia). There were very large variations in the use of anti-oedema agents, {\textquoteleft}cerebral vasodilators{\textquoteright}, and vitamins, which were not explained by differences in the populations studied. This variation has probably less to do with any scientific validation for the various treatments, which in most cases does not exist, than with medical {\textquoteleft}fashion{\textquoteright} and commercial pressures. Large variations in prescribing habits for what is thought to be the same disease are undesirable, and reflect a dearth of facts and adequate clinical trials. {\textcopyright} 1985 S. Karger AG, Basel.",

keywords = "Cerebrovascular disease, Drug treatment, Drug utilization",

author = "A. Spagnoli and G. Tognoni and I. Darmansjah and Laporte, {J. R.} and B. Vrhovac and Treacher, {D. F.} and Warlow, {C. P.}",

year = "1985",

month = jan,

day = "1",

doi = "10.1159/000115754",

language = "English",

volume = "24",

pages = "4--12",

journal = "European Neurology",

issn = "0014-3022",

number = "1",

}

TY - JOUR

T1 - A multinational comparison of drug treatment in patients with cerebrovascular disease

AU - Spagnoli, A.

AU - Tognoni, G.

AU - Darmansjah, I.

AU - Laporte, J. R.

AU - Vrhovac, B.

AU - Treacher, D. F.

AU - Warlow, C. P.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - We have compared the frequency with which various drugs were used in patients with cerebrovascular disease in five countries (UK. Italy, Indonesia, Spain and Yugoslavia). There were very large variations in the use of anti-oedema agents, ‘cerebral vasodilators’, and vitamins, which were not explained by differences in the populations studied. This variation has probably less to do with any scientific validation for the various treatments, which in most cases does not exist, than with medical ‘fashion’ and commercial pressures. Large variations in prescribing habits for what is thought to be the same disease are undesirable, and reflect a dearth of facts and adequate clinical trials. © 1985 S. Karger AG, Basel.

AB - We have compared the frequency with which various drugs were used in patients with cerebrovascular disease in five countries (UK. Italy, Indonesia, Spain and Yugoslavia). There were very large variations in the use of anti-oedema agents, ‘cerebral vasodilators’, and vitamins, which were not explained by differences in the populations studied. This variation has probably less to do with any scientific validation for the various treatments, which in most cases does not exist, than with medical ‘fashion’ and commercial pressures. Large variations in prescribing habits for what is thought to be the same disease are undesirable, and reflect a dearth of facts and adequate clinical trials. © 1985 S. Karger AG, Basel.

KW - Cerebrovascular disease

KW - Drug treatment

KW - Drug utilization

U2 - 10.1159/000115754

DO - 10.1159/000115754

M3 - Article

VL - 24

SP - 4

EP - 12

JO - European Neurology

JF - European Neurology

SN - 0014-3022

IS - 1

ER -

A multinational comparison of drug treatment in patients with cerebrovascular disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this